Evaluation and management of platelet transfusion refractoriness
Blood Research
;
: S6-S10, 2022.
Article
in English
| WPRIM
| ID: wpr-925636
ABSTRACT
Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Blood Research
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS